Tag: bioequivalence
Complex Generic Formulations: Why Proving Bioequivalence Is So Hard
Proving bioequivalence for complex generics like inhalers, topical creams, and liposomal injections is far harder than for regular pills. Without reliable tests, unclear regulations, and reverse-engineering hurdles, only 10-15% of these products get approved-despite a $120 billion market gap.
read more
Bioequivalence of Combination Products: Special Testing Challenges Explained
Bioequivalence testing for combination products like FDCs, topical creams, and inhalers is far more complex than for single-drug generics. Learn why these products face higher failure rates, regulatory hurdles, and how new science is helping generic makers bring down costs.
read more